How Protai’s AI-powered platform is improving drug discovery
Protai, an AI-powered drug discovery startup based in Tel Aviv, is revolutionizing the drug discovery and development process using proteomics and AI. The company’s platform maps diseases on the protein level, providing a better understanding of cellular function and improving the cost-effective discovery of new drugs. The company has secured $8 million in seed funding from leading venture capital investors such as Grove Ventures and Pitango Venture Capital. Protai’s technology has already moved beyond the research phase, with a proof-of-concept in lung cancer, and the company is collaborating with pharmaceutical companies on joint projects.
>> Click here to read the full article originally published in VentureBeat: How Protai’s AI-powered platform is improving drug discovery